Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells

被引:85
|
作者
Mego, Michal [2 ,3 ,4 ]
De Giorgi, Ugo [2 ,3 ]
Dawood, Shahenaah [3 ]
Wang, Xuemei [5 ]
Valero, Vicente [3 ]
Andreopoulou, Eleni [3 ]
Handy, Beverly [3 ]
Ueno, Naoto T. [3 ]
Reuben, James M. [2 ]
Cristofanilli, Massimo [1 ]
机构
[1] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA
[2] Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Dept Hematopathol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Dept Breast Med Oncol, Houston, TX 77030 USA
[4] Comenius Univ, Sch Med, Dept Med Oncol, Bratislava, Slovakia
[5] Comenius Univ, Sch Med, Dept Biostat, Bratislava, Slovakia
关键词
circulating tumor cells; prognostic factor; breast cancer; EPITHELIAL-MESENCHYMAL TRANSITION; PROGNOSTIC FACTORS; PERIPHERAL-BLOOD; CHEMOTHERAPY; SURVIVAL; SYSTEM;
D O I
10.1002/ijc.25690
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Circulating tumor cells (CTC) are an independent prognostic factor in metastatic breast cancer patients (MBC). However, CTC are undetectable in one third of patients. The aim of this study was to assess the prognostic factors in MBC patients without detectable CTC. This retrospective study included 292 MBC patients evaluated between January 2004 and December 2007. CTC were enumerated before patients started a new line of treatment using the CellSearch (TM). Overall survival (OS) was calculated from the date of CTC measurement and estimated by the Kaplan-Meier product limit method. CTC were not detected in 35.96% patients, whereas 40.75% patients had CTC >= 5. Undetectable CTC status was positively correlated with presence of brain metastasis (OR: 6.17, 95% CI 5 2.14-17.79; p = 0.001), and inversely correlated with bone metastasis (OR: 0.47; 95% CI = 0.27-0.80; p = 0.01). In multivariate analysis, hormone receptors, number of metastatic sites and lines of therapy were independent prognostic factors for OS in patients without detectable CTC. Patients without detectable CTC before starting of a new line of therapy comprise a heterogeneous group with substantially different prognosis. We showed that some important metastatic disease characteristics are predictive of undetectable CTC status in MBC.
引用
收藏
页码:417 / 423
页数:7
相关论文
共 50 条
  • [1] Longitudinal genetic characterization of circulating tumor cells in metastatic breast cancer patients
    Sero, Valeria
    De Luca, Francesca
    Doffini, Anna
    Galardi, Francesca
    Pestrin, Marta
    Czyz, Zbignew T.
    Buson, Genny
    Bregola, Giulia
    Bolognesi, Chiara
    Fontana, Francesca
    Medoro, Gianni
    Polzer, Bernhard
    Di Leo, Angelo
    Klein, Christoph A.
    Manaresi, Nicolo
    CANCER RESEARCH, 2015, 75
  • [2] Characterization of Circulating Tumor Cells in Breast Cancer Patients
    Lu, GuoFen
    Wu, Hui
    Ma, DeKui
    CLINICAL LABORATORY, 2023, 69 (07) : 1371 - 1380
  • [3] Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer
    Mu, Zhaomei
    Benali-Furet, Naoual
    Uzan, Georges
    Znaty, Anaelle
    Ye, Zhong
    Paolillo, Carmela
    Wang, Chun
    Austin, Laura
    Rossi, Giovanna
    Fortina, Paolo
    Yang, Hushan
    Cristofanilli, Massimo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (10)
  • [4] Circulating Tumor Cells in metastatic Breast Cancer
    Krawczyk, Natalia
    Meier-Stiegen, Franziska
    Katzorke, Nora
    Janni, Wolfgang
    Mueller, Volkmar
    Rack, Brigitte
    Fasching, Peter
    Wallwiener, Diethelm
    Albrecht, Susanne
    Fehm, Tanja
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2014, 74 (11) : 986 - 988
  • [5] Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients
    Bidard, Francois-Clement
    Madic, Jordan
    Kiialainen, Anna
    Birzele, Fabian
    Ramey, Guillemette
    Leroy, Quentin
    Frio, Thomas Rio
    Raynal, Virginie
    Bernard, Virginie
    Lermine, Alban
    Clausen, Inga
    Giroud, Nicolas
    Schmucki, Roland
    Horn, Carsten
    Spleiss, Olivia
    Lantz, Olivier
    Stern, Marc-Henri
    Weisser, Martin
    Lebofsky, Ronald
    Pierga, Jean-Yves
    CANCER RESEARCH, 2015, 75
  • [6] Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients
    Madic, Jordan
    Kiialainen, Anna
    Bidard, Francois-Clement
    Birzele, Fabian
    Ramey, Guillemette
    Leroy, Quentin
    Frio, Thomas Rio
    Vaucher, Isabelle
    Raynal, Virginie
    Bernard, Virginie
    Lermine, Alban
    Clausen, Inga
    Giroud, Nicolas
    Schmucki, Roland
    Milder, Maud
    Horn, Carsten
    Spleiss, Olivia
    Lantz, Olivier
    Stern, Marc-Henri
    Pierga, Jean-Yves
    Weisser, Martin
    Lebofsky, Ronald
    INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (09) : 2158 - 2165
  • [7] Characterization of Metastatic Breast Cancer Patients with Non-Detectable Circulating Tumor Cells.
    Mego, M.
    Dawood, S.
    De Giorgi, U.
    Valero, V.
    Andreoupolou, E.
    Handy, B. C.
    Ueno, N. T.
    Reuben, J. M.
    Cristofanilli, M.
    CANCER RESEARCH, 2009, 69 (24) : 648S - 648S
  • [8] In Vitro Cultivation of Circulating Tumor Cells of Metastatic Breast Cancer Patients
    Franken, A.
    Webers, A.
    Blassl, C.
    Niederacher, D.
    Melcher, C.
    Meznaric, S.
    Fehm, T.
    Neubauer, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 52 - 52
  • [9] Apoptotic Circulating Tumor Cells in Early and Metastatic Breast Cancer Patients
    Kallergi, Galatea
    Konstantinidis, Georgios
    Markomanolaki, Harris
    Papadaki, Maria A.
    Mavroudis, Dimitris
    Stournaras, Christos
    Georgoulias, Vassilis
    Agelaki, Sofia
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (09) : 1886 - 1895
  • [10] Characterization of circulating tumor cells from patients with metastatic bladder cancer
    Niu, Zeqi
    Kozminski, Molly
    Day, Kathleen C.
    Broses, Luke
    Henderson, Marian L.
    Merajver, Sophia
    Udager, Aaron
    Palmbos, Phillip L.
    Nagrath, Sunitha
    Day, Mark L.
    CLINICAL CANCER RESEARCH, 2024, 30 (10)